Zydus Says Teva Patents Violate Antitrust Laws

Law360, New York (October 28, 2008, 12:00 AM EDT) -- India-based pharmaceutical company Zydus Cadila’s U.S. subsidiary has filed a lawsuit against Teva Pharmaceutical Industries Ltd., accusing the Israeli generic-drug maker of deceptive trade practices related to the schizophrenia treatment risperidone.

Filed in the U.S. District Court for the Eastern District of Virginia on Oct. 14, the lawsuit accuses Teva of “deceptive,” “unconscionable” and “unlawful” trade practices in its marketing of the schizophrenia treatment and claims that its patents for risperidone are invalid.

“Teva's representatives have undertaken activities to tortiously interfere with Zydus' present and future...
To view the full article, register now.